Skip to main content

Kidney Failure

Nephrology
5
Pipeline Programs
10
Companies
9
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

  • GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
  • Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
  • Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1OZEMPICStable
$9.2B
Novo Nordisk·Peak12.4yr
#2JARDIANCEStable
$8.8B
#4FARXIGAStable
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists
$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors
$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)
$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists
$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors
$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

20Growing
8Stable

By Department

Commercial(47%)
$108K
Medical Affairs(10%)
$330K
Clinical Excellence(6%)
$140K
Quality Assurance(4%)
$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
ParicalcitolPhase 41 trial
Active Trials
NCT00294866Completed64Est. Jan 2008
Sandoz
SandozAustria - Kundl
1 program
1
cyclosporin + mycophenolate mofetilPhase 31 trial
Active Trials
NCT01595984Unknown90Est. Aug 2018
ITB Med
ITB MedNY - New York
2 programs
1
1
Bone Marrow TransplantPhase 1/2
Combined Kidney/Bone Marrow TransplantPhase 11 trial
Active Trials
NCT06972069Recruiting12Est. Dec 2030
Pfizer
PfizerNEW YORK, NY
1 program
1
Vfend®; I.V.Phase 1/21 trial
Active Trials
NCT00150319Terminated1Est. Oct 2005
Innovation Pharmaceuticals
1 program
Egg white protein puddingN/A1 trial
Active Trials
NCT06343727Recruiting54Est. Oct 2026
Eledon Pharmaceuticals
1 program
Combined Kidney/Bone Marrow TransplantPHASE_1
Ossium Health
Ossium HealthIN - Indianapolis
1 program
Bone Marrow TransplantPHASE_1_21 trial
Active Trials
NCT05900401Active Not Recruiting20Est. Dec 2030
Rockwell Medical
1 program
Soluble Ferric PyrophosphatePHASE_1_21 trial
Active Trials
NCT01894906Completed12Est. Sep 2013
Veloxis Pharmaceuticals
1 program
TacrolimusPHASE_21 trial
Active Trials
NCT00765661Completed63Est. Feb 2010
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
glecaprevir/pibrentasvir tabletsPHASE_41 trial
Active Trials
NCT03623568WithdrawnEst. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
T-Therapeuticsglecaprevir/pibrentasvir tablets
AbbottParicalcitol
Sandozcyclosporin + mycophenolate mofetil
Veloxis PharmaceuticalsTacrolimus
Ossium HealthBone Marrow Transplant
Rockwell MedicalSoluble Ferric Pyrophosphate
PfizerVfend®; I.V.
ITB MedCombined Kidney/Bone Marrow Transplant
Innovation PharmaceuticalsEgg white protein pudding

Clinical Trials (9)

Total enrollment: 316 patients across 9 trials

NCT03623568T-Therapeuticsglecaprevir/pibrentasvir tablets

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

Start: Feb 2019Est. completion: Apr 2021
Phase 4Withdrawn
NCT00294866AbbottParicalcitol

Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients

Start: Mar 2006Est. completion: Jan 200864 patients
Phase 4Completed
NCT01595984Sandozcyclosporin + mycophenolate mofetil

Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)

Start: May 2012Est. completion: Aug 201890 patients
Phase 3Unknown

Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients

Start: Sep 2008Est. completion: Feb 201063 patients
Phase 2Completed
NCT05900401Ossium HealthBone Marrow Transplant

Delayed Tolerance Through Mixed Chimerism

Start: Oct 2023Est. completion: Dec 203020 patients
Phase 1/2Active Not Recruiting
NCT01894906Rockwell MedicalSoluble Ferric Pyrophosphate

Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients

Start: Jul 2013Est. completion: Sep 201312 patients
Phase 1/2Completed
NCT00150319PfizerVfend®; I.V.

An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

Start: Jun 2005Est. completion: Oct 20051 patients
Phase 1/2Terminated
NCT06972069ITB MedCombined Kidney/Bone Marrow Transplant

Tolerance Through Mixed Chimerism (Sip-Tego)

Start: May 2025Est. completion: Dec 203012 patients
Phase 1Recruiting
NCT06343727Innovation PharmaceuticalsEgg white protein pudding

A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)

Start: Jul 2025Est. completion: Oct 202654 patients
N/ARecruiting

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 316 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.